Semaglutide is famous for weight loss. The SELECT trial's cardiovascular outcome data is the part of its evidence base that actually matters for longevity — and it's the least discussed.
Semaglutide became a household name for weight loss. The trial that matters most for longevity medicine measured something else entirely.
Semaglutide is FDA-approved for type 2 diabetes and, in higher-dose formulations, for chronic weight management — not for any longevity indication. Its relevance to longevity medicine comes from a separate body of evidence: the GLP-1 receptor agonist class's cardiovascular outcome data, most notably the SELECT trial (2023), which reported a pooled hazard ratio of 0.80 for major adverse cardiovascular events. That's a hard clinical outcome — not a surrogate marker like a blood test value — measured in a population that wasn't selected for diabetes.
Weight loss is a surrogate outcome — it's plausible that it contributes to better health, but it isn't itself a hard clinical endpoint like death or heart attack. The SELECT trial's MACE outcome is exactly the kind of evidence the longevity field is generally missing: a Phase III randomized trial with a hard outcome, in a broad population. This is precisely why GLP-1 agonists carry Geroevidence's Strong evidence tier — the highest tier on the platform's four-level ladder — while compounds with far more public attention, like NMN or senolytics, remain at Emerging.
A reduced cardiovascular event rate is not the same claim as "extends lifespan" or "treats aging." Gastrointestinal side effects are the most commonly reported; rare but serious risks identified in approved indications include pancreatitis and gallbladder disease, with long-term safety data continuing to accumulate as the drug class is more widely prescribed. "Anti-aging drug" is a framing applied by commentary and media, not an FDA-recognized indication or a claim Geroevidence makes.
The most commercially famous drug in the longevity-adjacent space also happens to have the strongest hard-outcome trial evidence of any compound Geroevidence tracks — but that evidence is about cardiovascular events, not aging itself. Whether GLP-1 agonists end up reshaping how the field thinks about pharmacological longevity intervention is a live question; what's already settled is the SELECT trial's outcome data, which stands on its own regardless of how the "anti-aging" framing evolves.